Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Online Discussions

Updated 26 April 2010 E-mail discussion
Printable version

Forum Discussion: Cognition in Mouse Models of Schizophrenia Susceptibility Genes


View article

In our Forum Discussion “journal club” series, the editors of journals provide access to the full text of a recent article. In this case, we thank the Schizophrenia Bulletin, not to mention Oxford University Press, for providing access to the full text of an article by Alexander Arguello and Joseph Gogos of Columbia University, New York City. A short introduction by Jim Koenig, of the Maryland Psychiatric Research Center, and author of SRF's Animal Models of Schizophrenia, gets us started, and then it's up to our readers to share their ideas and insights, questions, and reactions to the selected paper.

Arguello PA, Gogos JA. Cognition in Mouse Models of Schizophrenia Susceptibility Genes. Schizophr Bull. 2009 Dec 21. Abstract

View Comments By:
Craig M. Powell — Posted 21 April 2010
Jared Young — Posted 6 May 2010
Ina Weiner — Posted 19 May 2010
Jo Neill — Posted 27 May 2010
Alexander Arguello — Posted 21 June 2010


Background Text
By Jim Koenig, Professor, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore

Cognitive impairments remain as the most severely disabling symptom domain of patients afflicted by schizophrenia. The CNTRICS and MATRICS programs provided guidance for the identification of components of the cognitive domain that can be defined in patients with schizophrenia and that might be amenable to investigation in animal models for the disease. However, it is not clear whether these cognitive endophenotypes are related in terms of their pathophysiological bases. The use of well-defined genetic animal models and relevant cognitive endpoints may, however, begin to approach issues of common etiology, translatability, and potential pharmacological intervention strategies for components of the cognitive pathologies of schizophrenia.

The review authored by Arguello and Gogos describes the cognitive phenotypes present in genetic mouse models across the six domains of cognitive dysfunction articulated in the CNTRICS program. The authors focus their review on the mutant mouse preparations that are available for the top 30 candidate genes as identified 7 May 2009 in the SchizophreniaGene (SZGene) database. It is clear from this review that genetically manipulated mouse models are not available for all 30 of the leading candidate genes identified in the database. In addition, not all phenotypes have been tested in the available animal preparations. Nonetheless, this excellent review begins to analyze whether cognitive domains have a common genetic etiology or are only related at a behavioral level. Although the review is not exhaustive, there is sufficient detail provided to inform investigators about the state of this exciting area of research with strong clinical relevance. Some questions to consider include the following:

1. Are there one or two of these cognitive phenotypes that have more relevance or importance for improving the quality of life for a patient with schizophrenia?

2. There are many neurological diseases associated with cognitive dysfunction, including schizophrenia. Are there cognitive endpoints that may be more relevant to schizophrenia than other diseases?

3. Other than PPI and MMN, which of these cognitive endpoints, if any, could be exploited for high-throughput procedures?

4. The authors state: "The study of the mutant models reviewed above affords the opportunity to identify whether deficits within a cognitive domain converge merely at the behavioral level or whether there are common underlying neural correlates, and if so, how this may be related to diverse clinical phenotypes." Does this approach really allow investigators to grasp the "neural correlates" that might be involved?


Comments on Online Discussion
Comment by:  Craig M. Powell
Submitted 21 April 2010 Posted 21 April 2010

The conclusion of this paper, that we need better behavioral tests of higher-order cognitive function in rodent models to better mimic cognitive dysfunction in schizophrenia, does not seem very controversial. Currently, it seems most important to create a model with high constructive validity, to understand how brain function is perturbed in each model, to understand in detail how behavior is altered in each model, and to try to reverse brain function abnormalities to "treat" the behavioral abnormalities. Any efforts to create high-throughput cognitive tasks in rodent models are welcome and should be incorporated into the search for behavioral abnormalities in these disease models.

View all comments by Craig M. Powell


Comment by:  Jared Young
Submitted 6 May 2010 Posted 6 May 2010

The review of Arguello and Gogos provides a timely reminder of the importance of assessing the cognitive performance of genetic models of schizophrenia. Moreover, they provide a very nice oversight on transgenic/mutant lines available to date to investigate cognition in schizophrenia and the work that has been done to phenotype these mice.

The majority of transgenic mice discussed, however, are not specific to mutations observed in schizophrenia patients. Although they do discuss DRD2 knockout mice, it is surprising they did not discuss α7 nAChR knockout mice, despite the obvious relation to attentional performance.

Another surprise was that despite the admission that animal tasks of working memory likely measure short-term, not working memory, a large part of the review discusses evidence of performance of transgenic animals in tasks that have no proven efficacy for the working memory domains listed by CNTRICS. In fact, the only animal task listed by Barch et al. (2009)—when reporting working memory task...  Read more


View all comments by Jared Young

Comment by:  Ina Weiner
Submitted 19 May 2010 Posted 19 May 2010

Mouse models of schizophrenia susceptibility genes are crucial for studying the biological functions of genetic variants implicated in schizophrenia association studies. Arguello and Gogos's timely and informative review illustrates how such models are used to study the specific molecular alterations that may underlie some of the cognitive deficits of schizophrenia, or "the cognitive architecture related to genetic risk for schizophrenia."

The paper illuminates several issues worthy of consideration in this type of modeling. One is the issue of construct validity. As pointed out by the authors, when we evaluate cognition in genetic mouse models, we have two sources of construct validity: one that derives from the inducing factor/independent variable and one that derives from the behavioral manifestation/dependent variable: "…measuring relevant cognitive processes in animal models usually relies on the neuronal and psychological homology of these processes…. Using these criteria alone, however, may be problematic…. Additional support, like a solid genetic foundation, is...  Read more


View all comments by Ina Weiner

Comment by:  Jo Neill
Submitted 27 May 2010 Posted 27 May 2010

This excellent article is an extensive review of the relationship between mouse models of susceptibility genes for schizophrenia and their cognitive performance in tests of relevance to schizophrenia and the clinical situation. The article provides a considerable amount of relevant information concerning the schizophrenia susceptibility gene mouse models, and also highlights some of the wider issues in this field. One of the strengths of this review is the loud acknowledgement of the difficulties and inconsistencies in the field such as the uncertainty concerning which actual genes and alleles contribute most to the pathology of schizophrenia and the mechanism(s) by which they do so. One concern I think many researchers have about this work is the large number of schizophrenia susceptibility genes that have been identified, but their real significance in the clinic, and indeed usefulness, is unclear, except perhaps in the identification of certain rare alleles that account for a small number of cases as described in this paper.

This review also illuminates some broader...  Read more


View all comments by Jo Neill

Comment by:  Alexander Arguello
Submitted 21 June 2010 Posted 21 June 2010

We are grateful to SRF for featuring our review in this Journal Club series and thus providing this opportunity to answer questions and to discuss issues that, due to the narrow scope of the review and space limitations, we could not address. There were two major areas addressed by our review as highlighted by Dr. Weiner: 1) the creation of genetic models and 2) their behavioral characterization.

With regard to the first part, many commented on the genetic complexity of schizophrenia. I share the view that rare, highly penetrant mutations associated with disease are the best way forward for making rapid progress in understanding disease pathogenesis. While many common variants across the genome (like those listed in the SZGene database) may confer some small disease risk, it is just much easier to faithfully model and gain insight from a rare allele whose functional effect is known and whose effect size is large. That’s not to say common variants will have nothing to contribute to treatment, but in terms of genetic risk,...  Read more


View all comments by Alexander Arguello
Submit a Comment on This Online Discussion
Make a comment on this live discussion. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:



SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Live Discussion FAQs

Webinar: A Webinar is a seminar conducted remotely over the Web. Attendees view the slides through their Web browser and hear the presentations over their own telephones.

Registration: All participants are to register by clicking on the "Register for the Webinar" link.

Access: After you register, you will receive an e-mail with a link to the Webinar and a phone number.
New Schizophrenia Fact Sheet for Patients and Families

Latest BBRF Research Breakthroughs

Visit our Facebook page and our Blog.

Support the Brain & Behavior Research Foundation Today.

Research Participants
Collaborators
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright